EMA/666643/2017

European Medicines Agency decision

P/0315/2017

of 31 October 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for maribavir (EMEA-000353-PIP02-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0315/2017

of 31 October 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for maribavir (EMEA-000353-PIP02-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Shire Pharmaceuticals Ireland Limited on 19 December 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 September 2017, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for maribavir, tablet, tablet for oral suspension, powder for oral suspension, oral use, gastroenteral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for maribavir, tablet, tablet for oral suspension, powder for oral suspension, oral use, gastroenteral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Shire Pharmaceuticals Ireland Limited, 5 Riverwalk, Citywest Business Campus, 24 – Dublin, Ireland.

EMA/PDCO/436892/2017
London, 15 September 2017

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-000353-PIP02-16

Scope of the application

Active substance(s):

Maribavir

Condition(s):

Treatment of cytomegalovirus (CMV) infection

Pharmaceutical form(s):

Tablet

Tablet for oral suspension

Powder for oral suspension

Route(s) of administration:

Oral use

Gastroenteral use

Name/corporate name of the PIP applicant:

Shire Pharmaceuticals Ireland Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Shire Pharmaceuticals Ireland Limited submitted for agreement to the European Medicines Agency on 19 December 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 24 January 2017.

Supplementary information was provided by the applicant on 23 June 2017. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a waiver.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of cytomegalovirus (CMV) infection

2.1.1. Indication(s) targeted by the PIP

Treatment of CMV infection in paediatric patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Tablet for oral suspension

Powder for oral suspension

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of a powder or tablet for oral suspension.
Non-clinical studies	1	**Study 2** Definitive juvenile toxicity study in rats to evaluate potential gastrointestinal toxicity
Clinical studies	4	**Study 3** Double-blind, randomised, double-dummy, active-controlled trial to evaluate pharmacokinetics, safety, efficacy and acceptability of maribavir compared to valganciclovir for the treatment of asymptomatic CMV infection in adolescent and adult haematopoietic stem cell transplant (HSCT) recipients (SHP620-302). **Study 4** Open-label, randomised, active-controlled trial to evaluate pharmacokinetics, safety, efficacy and acceptability of maribavir compared to investigator-assigned anti-CMV treatment in adolescent

		and adult HSCT and solid organ transplant (SOT) recipients with refractory or resistant CMV infections (SHP620-303). **Study 5:** Open-label, randomised, single dose, two-treatment, two-period crossover study to assess the relative bioavailability, palatability, and safety/tolerability of the powder or tablet for oral suspension versus the adult tablet of maribavir in healthy adult volunteers (SHP620-1Xc). **Study 6:** Open-label, single-arm, repeated dose trial to evaluate pharmacokinetics, safety, tolerability, antiviral activity and acceptability/palatability of maribavir for the treatment of CMV infection in children and adolescents from birth to less than 18 years of age who have received a HSCT (SHP620-2Xd).
Extrapolation, modelling and simulation studies	2	**Study 7:** Modelling and Simulation study to support paediatric dose finding and the extrapolation of use of maribavir for the treatment of CMV infection in children from birth to less than 18 years of age. **Study 8:** Extrapolation study to support the use of maribavir for the treatment of CMV infections in children and adolescents from birth to less than 18 years of age who have received a SOT.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes